纳武利尤单抗持续治疗对比1年固定疗程在经治晚期非小细胞肺癌中的探索性分析:CheckMate 153
CheckMate 153是一项以社区为基础开展的IIIb/IV期研究,探索性分析经治晚期NSCLC患者接受纳武利尤单抗治疗1年后,持续治疗与固定1年疗程的疗效和安全性差异。结果显示,持续治疗组的中位PFS和中位OS均优于固定1年疗程组,且未发现新的安全性信号。
要点
- 持续纳武利尤单抗治疗超过1年可改善PFS和OS。
- 固定1年疗程组疾病进展后可选择再治疗。
- 两组均未观察到新的安全性信号。
核心结论
- 在经治晚期NSCLC中,持续纳武利尤单抗治疗超过1年较固定1年疗程可改善PFS和OS。
研究设计与样本
- CheckMate 153是一项以社区为基础的IIIb/IV期研究,经治晚期NSCLC患者接受纳武利尤单抗单药治疗(3 mg/kg 每2周)。
- 治疗1年时仍在治疗的患者(包括影像学进展但研究者认为仍获益者)随机分配至持续治疗组(n=127)或固定1年疗程组(n=125),共252例纳入意向治疗(ITT)分析。
- PFS分析集包括持续治疗组89例和固定1年疗程组85例随机分配时未进展的患者。
主要发现
- 随机分配后中位随访至少13.5个月,PFS分析集中持续治疗组中位PFS为24.7个月,固定1年疗程组为9.4个月(HR 0.56,95%CI 0.37-0.84)。
- PFS分析集中,持续治疗组中位OS未达到,固定1年疗程组为32.5个月(HR 0.61,95%CI 0.37-0.99)。
- ITT人群中,持续治疗组中位OS未达到,固定1年疗程组为28.8个月(HR 0.62,95%CI 0.42-0.92)。
- 两组新发治疗相关不良事件较少,未发现新的安全性信号。
临床怎么用
- 对于经治晚期NSCLC患者,纳武利尤单抗治疗1年后若仍在获益,可考虑持续治疗而非固定1年停药。
局限性
- 该分析为探索性分析,非主要终点设计。
- 研究以社区为基础,可能存在患者选择偏倚。
- 固定1年疗程组进展后可选择再治疗,可能影响OS比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab. METHODS: Patients with previously treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks). Those still receiving treatment at 1 year, including patients perceived to be deriving benefit despite radiographic progression, were randomly assigned to continue nivolumab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-study retreatment after disease progression (1-year fixed duration). RESULTS: Of 1,428 patients treated, 252 were randomly assigned to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). Of these, 89 and 85 patients in the continuous and 1-year fixed-duration arms, respectively, had not progressed (progression-free survival [PFS] population). With minimum post-random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixed-duration treatment (PFS population: 24.7 months v 9.4 months; hazard ratio [HR], 0.56 [95% CI, 0.37 to 0.84]). Median overall survival from random assignment was longer with continuous versus 1-year fixed-duration treatment in the PFS (not reached v 32.5 months; HR, 0.61 [95% CI, 0.37 to 0.99]) and ITT (not reached v 28.8 months; HR, 0.62 [95% CI, 0.42 to 0.92]) populations. Few new-onset treatment-related adverse events occurred. No new safety signals were identified. CONCLUSION: To our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.
引用
- Waterhouse DM, Garon EB, Chandler J, et al. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020. PMID: 32910710. doi:10.1200/JCO.20.00131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。